Amicus Therapeutics Inc

Amicus Therapeutics — FY2019 Earnings Presentation

24 slides from Amicus Therapeutics's earnings presentation, Mar 2, 2020

  1. Slide 1: 2019 Financial Results Conference Call & Webcast

    2019 Financial Results Conference Call & Webcast March 2, 2020

  2. Slide 2: Forward-Looking Statements

    Introduction 2 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinica

  3. Slide 3: A leading fully-integrated, global rare disease biotechnology company

    Introduction 3 A leading fully-integrated, global rare disease biotechnology company Gene Therapy World Class PLATFORM BIOLOGICS Protein Engineering Capabilities & Glycobiology AT-GAA EMPLOYEES Phase 3 in Robust R&D in 27 Countries Pompe Disease Engine Nearly 50+ Lysosomal GLOBAL Disorders and More

  4. Slide 4: Key Takeaways

    Introduction 4 Key Takeaways Recent successes across our science, clinical, regulatory and commercial efforts position us for the future Galafold Continues AT-GAA for Pompe Portfolio of Gene Strong Financial Strong Launch Advances Toward Therapy Programs Outlook with Current Performance & Approval a

  5. Slide 5: 2020 Key Strategic Priorities

    Introduction 5 2020 Key Strategic Priorities 1 Achieve global product revenue for Galafold of $250M-$260M Complete Pompe Phase 3 PROPEL study, enroll pediatric studies 2 and advance manufacturing to support 2021 BLA and MAA Advance clinical development, manufacturing and regulatory 3 discussions for

  6. Slide 6: Galafold (migalastat) Global Launch

    Galafold® (migalastat) Global Launch… …taking a leadership role in the treatment of Fabry disease “We push ideas as far and as fast as possible” - Amicus Belief Statement

  7. Slide 7: Galafold: Precision Medicine for Fabry Disease

    Galafold: Precision Medicine for Fabry Disease 7 Galafold Snapshot (as of December 31, 2019) Galafold is the cornerstone of Amicus’ success. It is an orally delivered small molecule precision medicine with a unique mechanism of action for Fabry patients with amenable variants that replaces the need

  8. Slide 8: 2019 Galafold Success

    Galafold: Precision Medicine for Fabry Disease 8 2019 Galafold Success Strong full-year revenue performance of $182M, exceeding guidance of $170M-$180M Quarterly Galafold Sales Year-over-Year Galafold Sales Growth 60.0 $55M 50.0 $49M -5% $44M 40.0 +105% $34M 30.0 $182M 20.0 $91M 10.0 0.0 1Q19 2Q19 3

  9. Slide 9: Galafold Growth Trajectory

    Galafold: Precision Medicine for Fabry Disease 9 Galafold Growth Trajectory Galafold is on track to generate $1B+ in projected cumulative revenues from 2020-2022 and is on an anticipated path to $500M+ in annual sales in 2023 and $1B+ annual sales at peak $500M+ $1B Annual Revenue $250M- $91M $182M

  10. Slide 10: AT-GAA: Next Potential Standard of Care for Pompe Disease

    AT-GAA: Next Potential Standard of Care for Pompe Disease “We encourage and embrace constant innovation” - Amicus Belief Statement

  11. Slide 11: FDA Granted BTD to AT-GAA in Late-Onset Pompe Disease

    AT-GAA for Pompe Disease 11 U.S. FDA Granted BTD to AT-GAA in Late-Onset Pompe Disease (LOPD) AT-GAA is the first ever second-generation product for any lysosomal disorder to earn FDA Breakthrough Therapy Designation (BTD) AT-GAA BTD Based on Ph 1/2 Clinical Efficacy • Improvements in 6-minute walk

  12. Slide 12: AT-GAA: Key Takeaways

    AT-GAA for Pompe Disease 12 AT-GAA: Key Takeaways • PROPEL pivotal study exceeded enrollment with data expected 1H2021 • Breakthrough Therapy Designation and the Promising Innovative Medicine designation highlight unmet need in AT-GAA for Pompe Pompe disease today Advances Toward • Plan to submit an

  13. Slide 13: Financial Summary

    Financial Summary “We are business led and science driven” - Amicus Belief Statement

  14. Slide 14: 2019 Select Financial Results

    Financial Summary 14 2019 Select Financial Results 2019 revenue of $182M from global Galafold sales Dec. 31, 2019 (in thousands, except per share data) Dec. 31, 2018 Product Revenue $182,237 $91,245 Cost of Goods Sold 21,963 14,404 R&D Expense* 286,378 270,902 SG&A Expense 169,861 127,200 Changes in

  15. Slide 15: Cash Runway Now to Well into 2022

    Financial Summary 15 Cash Runway Now to Well into 2022 (~2+ years) Fully funded through major milestones in portfolio and continued global growth $450M+ Well into Cash ~2+ Years Cash Runway 2022 YE2019

  16. Slide 16: Financial Outlook: Key Takeaways

    Financial Summary 16 Financial Outlook: Key Takeaways • Company fully funded through major milestones in portfolio and continued global growth • Cumulative Galafold projected revenue of $1B+ in 2020-2022 offsets significant majority of company spend/investments • Extended cash flow runway through Op

  17. Slide 17: Next Generation Gene Therapy Platform

    Next Generation Gene Therapy Platform “We have a duty to obsolete our own technologies” - Amicus Belief Statement

  18. Slide 18: Next Generation Gene Therapy Platform pipeline

    Next Generation Gene Therapy Platform 18 DISCOVERY PRECLINICAL PHASE 1/2 PHASE 3 REGULATORY COMMERCIAL Fabry Franchise Galafold®(migalastat) Monotherapy ODD Fabry Gene Therapy PENN Pompe Franchise AT-GAA (Novel ERT + Chaperone) ODD Pompe Gene Therapy PENN Batten Franchise – Gene Therapies CLN6 Batte

  19. Slide 19: Combines Amicus and Penn Expertise Across Lysosomal and Rare Diseases

    Next Generation Gene Therapy Platform 19 Combines Amicus and Penn Expertise Across Lysosomal and Rare Diseases An R&D platform with rights to 50+ diseases, including 8 active preclinical programs Protein Team of 200+ Engineering & scientists bringing Glycobiology expertise and Expertise Next- experi

  20. Slide 20: Gene Therapy: Updates & Key Takeaways

    Next Generation Gene Therapy Platform 20 Gene Therapy: Updates & Key Takeaways • CLN6 Phase 1/2 interim data shows profound impact with potential to become first ever approved gene therapy for fatal brain disease in children • Plan to report initial data for patients enrolled in CLN3 Phase 1/2 Portf

  21. Slide 21: Closing Remarks

    Closing Remarks “We are business led and science driven” - Amicus Belief Statement

  22. Slide 22: Thank You

    Thank You “Our passion for making a difference unites us” -Amicus Belief Statement

  23. Slide 23: Appendix

    Appendix Amicus Therapeutics

  24. Slide 24: Appendix Non-GAAP Reconciliation

    Appendix 24 Non-GAAP Reconciliation

Amicus Therapeutics — FY2019 Earnings Presentation on 6ix